drugset / Trial / NCT04475016
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
NaSingle-groupOpen-labelTreatment
Summary
Primary Objective:To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with nimotuzumab \& triprilimab as neoadjuvant treatment in locally advanced penile cancer.
Timeline
- Start
- 2020-08-12
- Primary completion
- 2022-05-06
- Completion
- 2022-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 1200 mg/m2 | Intravenous |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Triprilimab | Monoclonal antibody | 240 mg | Intravenous |